Singh A, Sohal A, Batta A. Recent developments in non-invasive methods for assessing metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 2024; 30(39): 4324-4328 [DOI: 10.3748/wjg.v30.i39.4324]
Corresponding Author of This Article
Akash Batta, DM, MD, Assistant Professor, Department of Cardiology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana 141001, Punjab, India. akashbatta02@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 21, 2024; 30(39): 4324-4328 Published online Oct 21, 2024. doi: 10.3748/wjg.v30.i39.4324
Recent developments in non-invasive methods for assessing metabolic dysfunction-associated fatty liver disease
Anmol Singh, Aalam Sohal, Akash Batta
Anmol Singh, Department of Medicine, Tristar Centennial Medical Center, Nashville, TN 37203, United States
Aalam Sohal, Department of Gastroenterology and Hepatology, Creighton University School of Medicine, Phoenix, AZ 85012, United States
Akash Batta, Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
Author contributions: Sohal A and Batta A designed the letter; Singh A and Sohal A performed the literature review and data collection; Batta A supervised the study and provided key feedback and suggestions; Singh A and Batta A analyzed the data and wrote the manuscript and subsequently revised it; All authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Akash Batta, DM, MD, Assistant Professor, Department of Cardiology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana 141001, Punjab, India. akashbatta02@gmail.com
Received: August 8, 2024 Revised: September 22, 2024 Accepted: September 25, 2024 Published online: October 21, 2024 Processing time: 64 Days and 9.8 Hours
Core Tip
Core Tip: Fibrosis-4 index, enhanced liver fibrosis, and magnetic resonance elastography are among the non-invasive tests (NITs) recommended by the American Association for the Study of Liver Disease for evaluation of patients at risk for or with established metabolic dysfunction-associated fatty liver disease (MAFLD). The recent non-invasive biomarkers of metabolic liver disease and liver investigation: Testing marker utility in steatohepatitis projects, have helped validate NITs for the detection of liver fibrosis and have significantly improved the reliability of NIT panels. While omics-based biomarkers present exciting possibilities, they are still in the early stages of clinical validation. The integration and combined use of various NITs appear to be the future direction for a more effective and precise assessment of MAFLD.
